Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

Share :
Published: 19 Jun 2014
Views: 2355
Rating:
Save
Dr John Seymour - Peter MacCallum Cancer Centre, Melbourne, Australia

At a press conference at EHA 2014, Dr Seymour presents the findings surrounding the use of an oral drug, ABT-199/GDC-0199 which was designed to exclusively mimic the binding of the “BH3” structural element to BCL-2 protein in CLL to restore the regulatory process that tells cancer cells to self-destruct.

Read the article or watch the interview for more.